According to a recent announcement, Larimar Therapeutics reported that all 7 sites of the open-label extension study were activated for assessing nomlabofusp in Friedreich ataxia.:
Source: Neurology Read More
Larimar Therapeutics Expects to Launch Pharmacokinetic Study for Pediatric Friedreich Ataxia by Year-End
Related Posts
<![CDATA[Novel Digital Measures for Tracking Disease
Progression in Duchenne Muscular Dystrophy Beyond Loss of
Ambulation]]>
<![CDATA[Novel Digital Measures for Tracking Disease Progression in Duchenne Muscular Dystrophy Beyond Loss of Ambulation]]>
